CorMedix Q2 2026 net income rises 31.1% to $26 million; revenue more than doubled to $101.9 million - CRMD News | RalliesCorMedix Q2 2026 net income rises 31.1% to $26 million; revenue more than doubled to $101.9 million
C
CRMD• Full-year outlook
- FY 2026 consolidated revenue guidance held at $325 million to $345 million.
- Adjusted EBITDA (non-GAAP) outlook was raised to $125 million to $140 million.
Second-quarter results
- CorMedix posted Q2 2026 consolidated revenue of $101.9 million, up 156.57% from a year earlier.
- Net income rose to $26 million; diluted EPS slipped to $0.29.
- Adjusted EBITDA (non-GAAP) climbed to $58.7 million from $22.4 million.
- DefenCath net revenue was $66.1 million; the acquired Melinta portfolio added $35.8 million.
•
